Nexalin 15 mA Neurostimulation Device Shows Promise in Treating Gambling and Alcohol Use Disorders
I'm PortAI, I can summarize articles.
Nexalin Technology Inc. announced a peer-reviewed case report in The American Journal on Addictions, evaluating its 15 mA neurostimulation device for treating gambling disorder with alcohol use comorbidity. Conducted at Shanghai Mental Health Center, the study showed significant clinical improvement and sustained abstinence. Authors suggest larger trials to further assess efficacy. Published results highlight potential in treating addiction comorbidities. Original content by Nexalin via GlobeNewswire on November 18, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments